Hypertension is the leading risk factor for cardiovascular disease and premature death
among women globally. However, there is a fundamental lack of knowledge regarding the …

Background: Accurately selecting hypertensive candidates for renal denervation (RDN)
therapy is required, as one-third of patients who undergo RDN are non-responders. We …

Background Renal sympathetic denervation (RDN) has been shown to lower arterial blood
pressure both in the presence and in the absence of antihypertensive medication in an …

Despite the availability of medications and advocacy for lifestyle interventions to address
hypertension (HTN), more than one-half of individuals with high blood pressure do not …

(1) Background: Sympathetic overactivity is a major contributor to resistant hypertension
(RH). According to animal studies, sympathetic overactivity increases immune responses …

Sympathetic overactivation is one of the main contributors to development and progress of
hypertension. Renal denervation (RDN) has been evidenced by series of clinical trials for its …

Hypertension constitutes a critical risk factor for cardio-cerebrovascular disease. Despite the
effectiveness of lifestyle adjustments and medications in blood pressure (BP) management …

Objectives: Renal sympathetic denervation (RDN) reduces blood pressure (BP). However,
one out of three patients does not exhibit a significant BP response to the therapy. This study …

Uncontrolled arterial hypertension is a major global health issue. Catheter-based renal
denervation has shown to lower blood pressure in sham-controlled trials and represents a …

Purpose To assess the variability of renal artery (RA) anatomy and presence of RA-
pathology in patients with mild-to-moderate hypertension enrolled in the RADIANCE-HTN …